89BIO Q2 2025 Earnings Report

89BIO EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.49
• Beat/Miss: N/A
• One Year Ago EPS: N/A

89BIO Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

89BIO Announcement Details

• Quarter: Q2 2025
• Date: 8/4/2025
• Time: Before Market Opens
• Conference Call Date: Monday, August 4, 2025
• Conference Call Time: 4:00PM ET

89BIO (NASDAQ:ETNB), Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for metabolic and fibrotic diseases. The company’s lead candidate, pegozafermin, is a long-acting, pegylated analog of fibroblast growth factor 21 (FGF21) designed to address underlying drivers of metabolic dysfunction, including liver fat accumulation, lipid abnormalities and inflammation. In addition to pegozafermin, 89bio is advancing a pipeline of next-generation FGF21-based molecules and receptor agonists aimed at treating a range of conditions linked to metabolic health.

Since its founding in 2018, 89bio has initiated multiple Phase 2 clinical trials evaluating pegozafermin in nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia and other disorders characterized by insulin resistance and liver fibrosis. Early-stage studies have demonstrated improvements in key biomarkers such as liver fat content, triglyceride levels and markers of liver injury. The company’s strategic focus on a biology-driven approach supports potential expansion into complementary indications, including cardiovascular disease and chronic kidney disease in patients with metabolic syndrome.

Based in South San Francisco, California, 89bio serves patients worldwide through its clinical partnerships and global trial network. The company was founded by a team of biotechnology veterans and academic scientists to translate foundational insights in hormone biology into practical therapies. Under the leadership of CEO and President Farhad Gen, Ph.D., 89bio has assembled a management team with deep experience in drug development, regulatory affairs and commercial strategy. The company is backed by leading life science investors and collaborates with research institutions to accelerate its pipeline toward regulatory milestones and potential commercialization.